SOME DRUG-RELATED PROBLEMS IN PRESCRIBING CANCER THERAPY AT THE DEPARTMENT OF MEDICINE OF AN ONCOLOGY HOSPITAL IN THE MEKONG DELTA

Kim Thuat Duong1,, Tran Ngoc Han Ho1, Hoang Mai Huong Van1, Minh Hai Nguyen1, Xuan Chu Duong2
1 Can Tho Oncology hospital
2 Can Tho University of Medicine and Pharmacy

Main Article Content

Abstract

Background: Drug-related problems (DRP) can affect the effectiveness of treatment and the safety of patients, especially with cancer treatment drugs. In Vietnam, there is little data on DRP in cancer patients. Objective: To determine the rate, and types of some drug-related problems in prescribing the first cycles of chemotherapy and factors related to the occurrence of  DRP. Materials and methods: A cross-sectional descriptive study was conducted on medical records of cancer patients receiving chemotherapy at the Internal Medicine Department of an Oncology Hospital in the Mekong Delta, from October 2022 to March 2023. DRP was determined by comparing the drugs used in the medical records to the references. DRPs were then classified according to the guidance of the Ministry of Health in Decision No. 3547/QD-BYT, July 22, 2021. Factors related to  the occurrence of DRP were determined by multivariable logistic regression model. Results: There were 196 medical records included in the study, the mean age of the patients was 56.2 (range 27 - 92), with 76.5% being female. A total of 175 DRPs were recorded across 115 medical records. The rate of medical records with at least one DRP was 58.7%, with an average of 0.9 DRP per medical record. Among the recorded DRPs, the most prevalent were related to dosage (82.3%), with the majority being doses lower than recommended (39.4%) and inappropriate timing of administration (38.9%). DRP related to drug selection accounted for 6.3% and those related to insufficient treatment accounted for 11.4%. Factors including male gender, older age (≥ 65 years old), and late stage (III, IV) increase the risk of DRP appearing. Conclusion: The prevalence of DRP was quite high in prescribing cancer chemotherapy. Appropriate interventions should be carried out to minimize DRP.

Article Details

References

1. Pharmaceutical Care Network Europe Association. PCNE Classification for Drug-Related Problems V9.1. 2020.
2. Sisay. E.A., Engidawork E., Yesuf. T.A., et. al. Drug Related Problems in Chemotherapy of Cancer Patients. Journal of Cancer Science and Therapy. 2015. 7:2, DOI: 10.4172/19485956.1000325.
3. Bộ Y tế. Quy định về mẫu phân tích thuốc và các vấn đề liên quan đến thuốc. Ban hành kèm theo Quyết định số 3547/QĐ-BYT ngày 22/7/2021 của Bộ trưởng Bộ Y tế. Hà Nội. 2021. 4. Bộ Y tế. Hướng dẫn thực hành dược lâm sàng cho dược sĩ trong một số bệnh không lây nhiễm. Ban hành kèm theo Quyết định số 3809/QĐ-BYT ngày 27/8/2019 của Bộ trưởng Bộ Y tế. Hà Nội. 2019. 5. Truven Health Analytics Micromedex 2.0.
6. Bộ Y tế. Ban hành Danh mục tương tác thuốc chống chỉ định trong thực hành lâm sàng tại các cơ sở khám bệnh, chữa bệnh. Ban hành kèm theo Quyết định số 5948/QĐ-BYT ngày 30/12/2021 của Bộ trưởng Bộ Y tế. Hà Nội. 2021.
7. Bạch Văn Dương, Nguyễn Thị Mai Lan và cộng sự. Phân tích các vấn đề liên quan đến thuốc trong kê đơn thuốc điều trị ung thư tại một bệnh viện chuyên khoa ung bướu. Tạp chí Y học Việt Nam. 2023. 527 (2), 294-299, https://doi.org/10.51298/vmj.v527i2.5905.
8. Degu A. , Kebede K. Drug-related problems and its associated factors among breast cancer patients at the University of Gondar Comprehensive Specialized Hospital, Ethiopia. Journal of oncology pharmacy practice. 2021. 27(1), 88-98, doi: 10.1177/1078155220914710.
9. Hoàng Thị Phương, Lê Bá Hải, Nguyễn Thị Thảo, và cộng sự. Mức ý nghĩa của can thiệp dược lâm sàng trên một số vấn đề liên quan đến thuốc trong kê đơn thuốc điều trị ung thư tại Bệnh viện Phụ Sản Trung ương. Tạp chí y học dự phòng. 2023. 33(4 Phụ bản), 105–112, https://doi.org/10.51403/0868-2836/2023/1233.
10. NCCN, Hematopoietic Growth Factors. Version 4.2021.
11. Venugopal J., Karnan D. Drug-related problems in cancer patients: A systematic review. J Oncol Pharm Pract. 2024 Apr;30(3):562-571, doi: 10.1177/10781552241229662.